Image of a researcher looking through a microscope
Source: Firebrick Pharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Biotechnology company PYC Therapeutics Ltd (ASX:PYC) has begun a follow-up study in the United States to assess the efficacy and safety of its drug candidate VP-001 to treat patients with blinding eye disease Retinitis Pigmentosa type 11 (RP11).

The latter condition – which develops in childhood – affects one in 100,000 people, and is caused by mutation in 1 copy of the PRPF31 gene leading to a protein insufficiency in photoreceptor and Retinal Pigment Epithelial (RPE) cells.

VP-001 – as the only drug candidate which has progressed to human trials for treatment of the condition – has been fast tracked by the US Federal Drug Administration (FDA).

The first candidate has been dosed as part of PYC’s multiple ascending dose (MAD) study which follows recent positive results yielded from a single ascending dose (SAD) study of VP-001 in patients with RP11.

Building on this knowledge, the company will dose patients in the MAD trial repeatedly with the two highest doses established as safe and well tolerated in the SAD trial – that is, 30 μg and 75 μg per eye – before assessing them for safety and efficacy endpoints.

Read-outs on these points are due for release before the end of 2024, and are set to support PYC’s design of the registrational trial required to facilitate a New Drug Application for this candidate, which will commence in 2025.

PYC has been trading at 12 cents.

PYC by the numbers
More From The Market Online
Uranium ore in a mine

AR3 hits shallow, calcrete-hosted uranium at Overland, across 1km zone

Australian Rare Earths Ltd has conducted drilling at its Overland project in South Australia which has…
The Market Online Video

ASX Market Open: Wall Street returns to sell-off trend ahead of Fed policy decision | March 19, 2025

The Aussie market is expected to open lower today, echoing falls across the three Wall Street…
Gold silver and copper

Great Western predicts large VHMS system after one hole program at Oval

Great Western Exploration Ltd has drilled one hole into its Oval target in Western Australia, yielding…
The Market Online Video

ASX Market Close: Index pares gains, Gold hits new record | March 18, 2025

The ASX200 pared early gains to close up by a sliver of less than a tenth of a percent at 7860 points.